Cart
sales@molnova.com
Efalizumab
CAS No. 214745-43-4
Efalizumab( —— )
Catalog No. M36773 CAS No. 214745-43-4
Efalizumab, a novel potent regulator of T cells, is a humanized LFA-1 α subunit (CD11a) monoclonal antibody.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 487 | In Stock |
|
| 10MG | 778 | In Stock |
|
| 25MG | 1159 | In Stock |
|
| 50MG | 1516 | In Stock |
|
| 100MG | 2065 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEfalizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionEfalizumab, a novel potent regulator of T cells, is a humanized LFA-1 α subunit (CD11a) monoclonal antibody.
-
DescriptionEfalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research.
-
In VitroEfalizumab (78 ng/mL-5 mg/mL) induces a leukocytosis and downregulates LFA-1 expression on T cells in the peripheral blood.Efalizumab (78 ng/mL-5 mg/mL) downregulates plate-bound, anti-CD3-stimulated proliferation of PBMC.
-
In VivoEfalizumab shows side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number214745-43-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S98-104. ?
molnova catalog
related products
-
Cyclo(RGDyK)
Cyclo(RGDyK) (Cyclic Arg-Gly-Asp-D-Tyr-Lys) is a cyclic derivative of RGD, potent, selective αVβ3 integrin inhibitor with IC50 of 20 nM.
-
Integrin-IN-27
A potent integrin αvβ3 antagonist with IC50 of 18 nM; could be conjugated to paclitaxel for selective delivery to alphavbeta3 positive metastatic cancer cells.
-
Abciximab
Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor.
